par Messin, Roger 
Référence The American heart journal, 109, 3 II, page (667-669)
Publication Publié, 1985
Référence The American heart journal, 109, 3 II, page (667-669)
Publication Publié, 1985
Article révisé par les pairs
| Résumé : | Using a randomized, double-blind, crossover protocol, we compared the effects of oral molsidomine (Corvaton, 6 mg/day) and placebo, administered alternately for two 14-day periods, on the exercise tolerance of 25 outpatients with coronary heart disease. Resting heart rate and oxygen consumption increased by 6.8% (p < 0.005) and 12.6% (p < 0.01), while peripheral systolic blood pressure was reduced by 5.1% (p < 0.05). At submaximal workloads, systolic and diastolic blood pressures were reduced by 5.6% (p < 0.001) and 6.1% (p < 0.001), the pressure-rate product was reduced by 8.5% (p < 0.05), and ST segment depression was reduced by 40.0% (p < 0.005). At maximal exercise level, mechanical power increased by 32.4% (p < 0.001) and oxygen consumption by 15.5% (p < 0.005), while ST segment depression was reduced by 30.6% (p < 0.001). No alteration was found in postexercise lung function tests. It is concluded that molsidomine reduces myocardial ischemia at both submaximal and maximal work levels and increases exercise tolerance significantly. These effects could be related to reduced myocardial oxygen requirements, reflected in a lower pressure-rate product at submaximal exercise and perhaps enhanced by a lower preload, which, moreover, would favor coronary flow in subendocardial layers. The drug had no adverse bronchopulmonary effects. |
